Welcome to our dedicated news page for 23andMe Holding Co. Class A (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23andMe Holding Co. Class A .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 23andMe Holding Co. Class A 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 23andMe Holding Co. Class A 's position in the market.
Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) will present preliminary efficacy and biomarker data for 23ME-00610 at the 2024 ASCO Annual Meeting. The Phase 1/2a clinical trial data for neuroendocrine and ovarian cancer patient cohorts will be showcased. 23andMe identified CD200R1 as a promising immuno-oncology target through genetic and health data analysis. Clinical data has shown favorable pharmacokinetics and safety profile for 23ME-00610.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
-
Rhea-AI Summary
23andMe Holding Co. announces that CEO Anne Wojcicki is considering a proposal to acquire all outstanding shares of the company, potentially taking it private. Ms. Wojcicki, who currently owns over 20% of the shares, aims to maintain control and will not support alternative transactions. The Board formed a Special Committee to review strategic options, including the proposal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.91%
Tags
-
Rhea-AI Summary
23andMe Holding Co. (ME) to present data on clinical stage programs targeting ULBP6 and CD200R1 at AACR Annual Meeting 2024. The company's antibodies show potential in restoring anti-tumor immunity and enhancing immune response in cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
Rhea-AI Summary
23andMe Holding Co. announced the dosing of the first participant in a Phase 1 clinical trial for 23ME-01473 ('1473), a drug targeting ULBP6 to restore anti-tumor immunity. The drug aims to enhance NK and T cells' effector function and induce Fc receptor-mediated killing of cancer cells. This marks the third drug target validated by 23andMe's research platform to enter clinical trials in under 4 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
-
Rhea-AI Summary
23andMe Holding Co. (ME) introduces Historical Matches feature connecting customers to 335 unique historical individuals, including enslaved and free Black and African Americans. The feature utilizes advanced science to uncover DNA connections with historical figures like Ludwig Van Beethoven and ancient African hunter-gatherers. This groundbreaking offering sets a new standard in genetic matching, providing customers with a deep dive into their ancestral connections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
-
Rhea-AI Summary
23andMe introduces new genetic reports for breast, colorectal, and prostate cancer based on polygenic risk scores (PRS), aiming to provide customers with insights into their likelihood of developing these cancers. The PRS reports utilize thousands of genetic variants to calculate individual risk, with a focus on early-onset diagnoses and the importance of genetics in healthcare. Limitations include ethnicity-based availability and the exclusion of all genetic variants associated with hereditary cancer syndromes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.9%
Tags
Rhea-AI Summary
23andMe announces presentations on genetic signature ULBP6 and immuno-oncology programs at AACR Annual Meeting 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.9%
Tags
-
Rhea-AI Summary
23andMe (ME) faced a massive data breach in December 2023, impacting 7 million users. Hackers targeted Jewish and Chinese customers, selling their genetic information on the dark web. The company failed to disclose this targeting, leading to potential risks for affected customers. Lawsuits have been filed, alleging negligence and lack of transparency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.63%
Tags
-
Rhea-AI Summary
23andMe (ME) faced a significant data breach in December 2023, impacting 7 million users, with hackers targeting Jewish and Chinese customers' personal genetic information. The hackers compiled lists of customers' data, including heritage, names, and addresses, which were sold on the dark web. The lawsuit revealed that the hacker leaked lists of Jewish and Chinese customers, posing a threat to their safety. Despite the breach, 23andMe has not informed the compromised customers about their exposed information. The company faces legal action for concealing crucial details from affected customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.45%
Tags
Rhea-AI Summary
23andMe (ME) faced a massive data breach in December 2023, affecting 7 million users, with hackers specifically targeting Jewish and Chinese customers. The personal genetic information, including heritage, names, and addresses, was compiled into lists and sold on the dark web. The breach poses a significant threat to customer safety, especially from potential government tracking. 23andMe has been accused of not informing compromised customers about the breach, leading to a class-action lawsuit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
23andMe Holding Co. Class A
Nasdaq:ME
ME Rankings
ME Stock Data
241.60M
312.08M
3.94%
43.11%
6.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SOUTH SAN FRANCISCO
About ME
23andme is the leading personal genetics company dedicated to helping individuals understand their own genetic information through dna analysis technologies and web-based interactive tools. the company's personal genome service® enables individuals to gain deeper insights into their ancestry and genetic make-up. the vision for 23andme is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andme was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science.